Medtronic PLC (NYSE:MDT) launched new products that aim to help in diagnosis and treatment of coronary conditions. The new products include the DxTerity Diagnostic Angiography Catheter line. The other products are transradial specific and include the DxTerity TRA, TRAcelet compression device, and the InTRAkit access kit.
The Food and Drug Administration has cleared all these products. Also, they have the CE (Conformité Européenne) mark, meaning they can be used for diagnosis of cardiac catheterization procedures in both the USA and Europe.
The Use Of These Interventions
The DxTerity Diagnostic Angiography Catheters and the DxTerity TRA Diagnostic Catheters will both be used in determining the need for revascularization in patients with coronary heart diseases. The DxTerity TRA diagnostic catheters use transradial technology to allow access to the coronary arteries, alienating the need for a catheter exchange.
The TRAcelet compression device facilitates reduction of pressure during post-transradial catheterization, by maintaining radial artery patency, while ceasing any bleeding. The InTrakit access kit enhances the transradial access.
Medtronic PLC (NYSE:MDT) also launched the Transradial Arc Curriculum in the USA. The purpose of the curriculum is to provide comprehensive clinical training to physicians, medical staff, and hospital administrators so that there can be the smooth adoption of the transradial treatment approach in coronary disease patients. The Transradial Arc Curriculum is only available in the USA.
The Transradial Approach Is Effective
According to Jason Weidman, the president of the Coronary and Renal Denervation department at Medtronic, the aim of the recent developments is to “help accelerate the adoption of transradial approach.” According to him, there are so many benefits this approach can bring to both patients and medical practitioners.
According to a meta-analysis of random studies, the transradial approach, which is conducted through a patient’s wrist), results in low cost of treatment, reduction in vascular complications and bleeding associated with other treatment methods, and reduction in deaths related to coronary diseases.
Medtronic PLC (NYSE:MDT) is based in Dublin, Ireland. It is a world leader in the research and development of medical technologies, especially in the cardiovascular field. Their products focus on treatments of conditions as well as cost effectiveness. Its mission is to take health care further.
Medtronic stock closed at $77.05 per share, after rising $0.13 or 0.17% in Tuesday’s trading session.
Note: This article is written by Adam Russell and originally published at Market Exclusive.